Medical Device

Beyond Medical Technologies Inc. is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc.

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. ("Micron Technologies").

New Variant of COVID-19

In response to the discovery of a new COVID-19 variant the federal government of Canada is implementing a travel ban on several south African countries including South Africa, Mozambique, Namibia, Zimbabwe, Botswana, Lesotho and Eswatini. In addition to Canada, the European Union, Israel, Japan, India, and Great Britain have all imposed travel bans on numerous South African countries. The restrictions have been implemented following the discovery of a new variant of COVID-19 in South Africa. South Africa's Minister of Health, Joe Phaahla, stated, "Initially, it looked like some cluster outbreaks, but from yesterday, the indication came from our scientists from the Network of Genomic Surveillance that they were observing a new variant."

The World Health Organization (WHO) declared the new variant identified in South Africa, named "Omicron", as a "variant of concern". The WHO deems new variants to be either a "variant of interest" or a "variant of concern", the latter being the more serious of the two. Further, a statement issued by the WHO on Friday stated "this variant has a large number of mutations, some of which are concerning" and that evidence gathered thus far indicates that the variant carried a higher risk of reinfection than other variants.

Manufacturing Three-Ply Medical Grade Face Masks at Full Capacity

Micron Technologies has been manufacturing and selling three-ply medical grade Level 3 face masks in Delta, B.C. since August 2020. Micron Technologies is manufacturing three-ply medical grade face masks pursuant its Medical Device Establishment License issued by Health Canada. Micron Technologies is also registered with the U.S. Food and Drug Administration.

Micron Technologies is currently operating two shifts per day to manufacture three-ply medical grade face masks. The three-ply medical grade face masks, which feature an adjustable nose clip designed to protect both front-line workers and consumers, offer three layers of protection and conform to the American Society for Testing and Materials' F2100 Level 3 standards.

Products for Retail

As previously announced, Micron Technologies' medical grade face masks are available to purchase through Walmart, Amazon and Shopify. Micron Technologies' black medical grade three-ply masks have achieved the status of '#1 best seller' on Amazon.

Institutional customers and those who are interested in obtaining a quote for large size orders are encouraged to contact or Customers can also make orders directly at

About Beyond Medical

Beyond Medical is an industrial/technology company with a manufacturing facility located in Delta, B.C. The Company, through its subsidiary Micron Technologies, manufactures medical grade face masks. For further information contact:

Kal Malhi, CEO

The Company is not making any express or implied claims that its products have the ability to eliminate, cure or contain COVID-19 (or SARS-2 Coronavirus) at this time.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.


This news release includes certain statements that may be deemed "forward-looking statements". All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.


Beyond Medical Technologies

Beyond Medical Technologies


Beyond Medical Technologies (CSE:DOCT,FWB:7FM2)is a Canadian manufacturing company working to deliver essential safety equipment to protect citizens from airborne pathogens. The company’s flagship manufacturing facility is located in Delta, British Columbia, offers a fully-stable environment where it can produce technologically-enhanced personal protective equipment (PPE). Beyond Medical Technologies has invested significantly in the latest production and sterilization technology that it hopes will enable the production of high-grade protective medical equipment.

The COVID-19 crisis around the world has Beyond Medical Technologies focusing its manufacturing capacity on three core groups of users in need: hospitals, consumers and non-governmental organizations (NGOs). The company’s aim is to leverage technology to rapidly develop and produce masks and other protective equipment capable of protecting against common pathogens.

Mask use is recommended by public health authorities around the world as one of the leading means of preventing the spread of airborne viruses and diseases. During the COVID-19 pandemic, the widespread use of masks has been effective in reducing the “reproductive number” of the virus to below 1.0, a critical threshold.

“Societal norms and government policies supporting the wearing of masks by the public, as well as international travel controls, are independently associated with lower per-capita mortality from COVID-19,” concluded Virginia Commonwealth University’s Department of Ophthalmology in one study concerning mask use and global mortality rates.

Beyond Medical Technologies’ manufacturing facility in Delta, British Columbia is located close to major shipping hubs connected by rail, air and sea. The company anticipates this access to international distribution channels could allow it to quickly service regions around the world. Beyond Medical Technologies is targeting the global personal protective equipment (PPE) market, which is expected to grow to a total of US$84.7 billion by 2027 according to Grand View Research.

The company intends to continue to build out its manufacturing facility while developing proprietary products and increasing its existing portfolio through innovations and further acquisitions.

Beyond Medical Technologies Goal

Beyond Medical Technologies prides itself on being a Canadian company with the goal of first protecting and satisfying the needs of Canadian citizens. Considering the severity of the COVID-19 pandemic, Beyond Medical Technologies is working to advance and scale its operations in order to support the global need for protective equipment as well.

The next catalyst for Beyond Medical Technologies is to secure a NIOSH N95 certification, while also exploring the potential of establishing a sterilization service for mask re-use.

Company Highlights

  • State-of-the-art 5,078 square foot manufacturing facility is based in Delta, British Columbia with access to local shipping and distribution centers
  • Targeting the global PPE market, expected to grow by US$84.7 billion by 2027 according to Grand View Research
  • Working to produce medical-grade masks capable of preventing the spread of airborne pathogens
  • Mask use has been proven by various studies to greatly reduce the reproductive number of the coronavirus
  • Working towards vertical integration in the medical space by establishing melt-blown polypropylene fabric production
  • The company’s wholly-owned subsidiary Micron Technologies achieves the Amazon Choice designation and begins to accept bitcoin payments for its Canada made face masks.

Manufacturing Facility

Through its subsidiary Covid Technologies Inc, Beyond Medical Technologies has established its flagship 5,078-square foot manufacturing facility in Delta, British Columbia. The facility has been designed to leverage cutting-edge manufacturing technology in order to provide effective medical safety equipment to the hospitals, NGOs and consumers that need them most. The facility benefits from nearby distribution channels with the potential to quickly distribute Beyond Medical Technologies’ product by air, rail and sea.

Beyond Medical Technologies has begun acquiring mask-making equipment and materials needed for production, including an FLK120 surgical mask-making machine and over five tonnes of raw material. Through its subsidiary, Beyond Medical Technologies has secured an interim MEDL Licence (Medical Device Licence) and is working towards the production of Class 1 Protective 3ply Surgical masks, including the ASTM F2100 and F2101, neither of which require a license to manufacture.

Beyond Medical Technologies Products

Beyond Medical Technologies intends to begin with the development and production of surgical masks that can be used as PPE. As of Q2 2020, the company has begun the initial acquisition stage of mask filter production. Moving forward, Beyond Medical Technologies is working to acquire a melt-blown machine line capable of producing up to at least 3,200 kilograms of melt-blown polypropylene fabric per day. Beyond Medical Technologies hopes to be able to manufacture N95 Respirators and is awaiting a license from NIOSH (National Institute for Occupational Safety and Health (NIOSH).

Management Team

Kulwant Malhi “Kal”- Chairman, President and Chief Executive Officer

Before becoming the CEO of Beyond Medical, Mr. Malhi founded five different companies, including Patriot One Technologies, Inc., BullRun Capital, Inc. (Canada), and Cannabix Breathalyzer, Inc.

Mr. Malhi is an entrepreneur and businessperson who previously lead 11 different companies and occupied the position of Chairman for First Responder Technologies, Inc., President, Chief Executive Officer & Director at Cairo Resources, Inc., President & Director at Algernon Pharmaceuticals, Inc., Principal at Cannabix Breathalyzer, Inc. (he founded the company), Chairman for Micron Waste Technologies, Inc. (he founded the company) and Member of Royal Canadian Mounted Police.

Zara Kanji - Chief Financial Officer

Zara Kanji is a founder of Zara Kanji & Associates, CPA (est. 2004). Ms. Kanji is experienced in financial reporting compliance for junior listed companies, taxation, general accounting, financial reporting and value-added advisory services for individuals, private and public companies. Ms. Kanji has served as director and officer for listed issuers providing reporting compliance services for financing and acquisitions. Additionally, Ms. Kanji is a member of the Chartered Professional Accountants of B.C. (Previously Certified General Accountants of B.C.) since August, 2003.

Johnson & Johnson to Participate in Citi's 2022 Virtual Healthcare Conference

- Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on Wednesday, February 23 rd Ashley McEvoy Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time) .

This conference call will be available to investors and other interested parties by visit the Johnson & Johnson website at .

Keep reading... Show less

Thermo Fisher Scientific Earns Top Score for LGBTQ+ Workplace Equality for Seventh Consecutive Year

Thermo Fisher Scientific Inc., (NYSE:TMO), the world leader in serving science, received a score of 100 on the Human Rights Campaign Foundation's 2022 Corporate Equality Index (CEI) for the seventh consecutive year. As the national benchmarking tool measuring policies, practices and benefits pertinent to lesbian, gay, bisexual, transgender and queer (LGBTQ) employees, the CEI is a driving force for LGBTQ+ workplace inclusion.

Keep reading... Show less

Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $1.0 billion aggregate principal amount of new senior secured notes due 2027 (the "Notes"). As previously announced, the Company is also seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the "New Term B Loans") and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur upon completion of the initial public offering ("IPO") of Bausch + Lomb Corporation ("Bausch + Lomb" and such offering, the "Bausch + Lomb IPO") and a related debt financing by Bausch + Lomb (the "Bausch + Lomb Debt Financing").

The proceeds from the offering of the Notes, along with the expected proceeds from the New Term B Loans, the Bausch + Lomb IPO and the repayment of an intercompany note owed to us by Bausch + Lomb (which repayment is expected to be funded by the Bausch + Lomb Debt Financing), are expected to be used to fund the Company's previously announced conditional redemption in full of its outstanding 6.125% Senior Notes due 2025 (the "6.125% Notes due 2025"), refinance all of the existing Term B Loans, fund the Company's previously announced conditional partial redemption of its outstanding 9.000% Senior Notes due 2025 (the "9.000% Notes due 2025 and, collectively with the 6.125% Senior Notes due 2025, the "Existing Notes") and to pay related fees, premiums and expenses.

Keep reading... Show less

Danaher Reports Fourth Quarter And Full Year 2021 Results

- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2021. All results in this release reflect only continuing operations unless otherwise noted.

For the quarter ended December 31, 2021 , net earnings were $1.8 billion , or $2.39 per diluted common share which represents a 44.0% year-over-year increase from the comparable 2020 period.

Keep reading... Show less

Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast

Abbott (NYSE: ABT) today announced financial results for the fourth quarter and full year ended Dec. 31, 2021 and issued its financial outlook for 2022.

  • Fourth-quarter sales of $11.5 billion increased 7.2 percent on a reported basis and 7.7 percent on an organic basis, which excludes the impact of foreign exchange.
  • Fourth-quarter GAAP diluted EPS was $1.11 and adjusted diluted EPS, which excludes specified items, was $1.32 .
  • Full-year 2021 GAAP diluted EPS from continuing operations was $3.94 and adjusted diluted EPS from continuing operations was $5.21 , reflecting 42.7% growth versus the prior year. 1
  • Global COVID-19 testing-related sales were $2.3 billion in the fourth quarter and $7.7 billion for the full-year. Abbott has distributed more than 1.4 billion COVID-19 tests since the start of the pandemic.
  • Abbott issues full-year 2022 guidance for diluted EPS from continuing operations on a GAAP basis of at least $3.43 and full-year adjusted diluted EPS from continuing operations of at least $4.70 .
  • Full-year 2022 guidance includes an initial COVID-19 testing-related sales forecast of $2.5 billion , which Abbott expects to occur early in the year and will update on a quarterly basis.
  • Abbott's R&D pipeline continues to deliver a steady cadence of new products. Select 2021 highlights include U.S. Centers for Medicare & Medicaid Services expanded reimbursement for MitraClip ® , U.S. launches of Amplatzer ® Amulet ® , NeuroSphere Virtual Clinic, and Portico ® transcatheter aortic valve replacement (TAVR) system, along with the international launch of Navitor TAVR system.

"2021 was an outstanding year for Abbott," said Robert B. Ford , chairman and chief executive officer, Abbott. "We achieved more than 40 percent EPS growth, exceeding the baseline EPS guidance we set at the beginning of last year and, importantly, continued to advance our new product pipeline across the portfolio."

Keep reading... Show less
Avricore Health CEO and Special Guests Join Radius Research for Investor Update

Avricore Health CEO and Special Guests Join Radius Research for Investor Update

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is excited to be joined by Shoppers Drug Mart Pharmacist and Associate Owner, Mohamad Adel Elsabakhawi and Abbott Rapid Diagnostics' General Manager Daniel St. Pierre and National Sales Manager, Soul Khan.

"The Company enjoyed an incredible year in 2021, and throughout the Holidays and the beginning of the New Year, we have continued to finalize key agreements which will lead to substantial growth this year." said Avricore Health CEO, Hector Bremner. "Our partners are as excited as we are and we look forward to deepening our collaboration."

Keep reading... Show less

Latest Press Releases

Related News